Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03275740 · ClinicalTrials.gov registry record · Phase 1
A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347
A Phase 1 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 58
- Enrollment target
NCT03275740 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 58 participants.
The verdict
NCT03275740, a Phase 1 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 58 participants
- Enrollment target
Study Summary
This phase 1 single ascending dose study will provide a first in human assessment of safety and tolerability of PF-06755347 in healthy adult males as well as adult males and females with Immune Thrombocytopenia (ITP). Pharmacokinetics and pharmacodynamics will also be evaluated.
Interventions
- DRUG PF-06755347 intravenous healthy participant
- DRUG Placebo intravenous healthy participant
- DRUG PF-06755347 subcutaneous healthy participant
- DRUG Placebo subcutaneous healthy participant
- DRUG PF-06755347 subcutaneous ITP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2017-07-17 |
| Est. Completion | 2023-01-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03275740
The ClinicalTrials.gov registry entry for NCT03275740 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which PF-06755347 intravenous healthy participant is the first listed.
NCT03275740 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03275740 about?
NCT03275740 is a clinical study titled "A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347". This phase 1 single ascending dose study will provide a first in human assessment of safety and tolerability of PF-06755347 in healthy adult males as well as adult males and females with Immune Thrombocytopenia (ITP). Pharmacokinetics and pharmacodynamics will also be evaluated.
What is the current status of trial NCT03275740?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 58 participants. The study started on 2017-07-17. Estimated completion is 2023-01-06.
What interventions are being tested in trial NCT03275740?
The interventions under investigation include: PF-06755347 intravenous healthy participant (DRUG), Placebo intravenous healthy participant (DRUG), PF-06755347 subcutaneous healthy participant (DRUG), Placebo subcutaneous healthy participant (DRUG), PF-06755347 subcutaneous ITP (DRUG).
Who is sponsoring clinical trial NCT03275740?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.